Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Details : Under the license agreement, Acadia will acquire exclusive rights to further the clinical development of SAN711, which is being studied as a treatment for Essential Tremors.
Product Name : SAN711
Product Type : Other Small Molecule
Upfront Cash : $28.0 million
November 26, 2024
Io Therapeutics Presents IRX4204 Data for Aging, Parkinson’s, and Alzheimer’s
Details : IRX4204 is a highly potent and highly selective, orally available, third generation RXR agonist compound which IS being tested in early phase clinical trials in patients with Parkinson’s disease
Product Name : IRX4204
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo's Older Obesity Drug Shows Biological Effect on Alzheimer's Patients in Small Trial
Details : Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is investigated for the treatment of patients with mild alzheimer's disease.
Product Name : Victoza
Product Type : Peptide
Upfront Cash : Inapplicable
July 29, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vesper Bio Completes Single Ascending Dose Stage for VES001 in Dementia Trial
Details : VES001, a oral small molecule sortilin receptor inhibitor, is presently completed Phase I evaluation for the treatment of Frontotemporal Dementia.
Product Name : VES001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2024
Vesper Bio Reports Successful Phase I Study for Frontotemporal Dementia Treatment
Details : VES001 is a first-in-class oral, brain-penetrant, small molecule sortilin receptor inhibitor, is presently undergoing evaluation for the treatment of Frontotemporal Dementia.
Product Name : VES001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2024
Details : VES001, a small molecule sortilin receptor inhibitor, is presently undergoing evaluation in ongoing Phase I clinical trials for the treatment of Frontotemporal Dementia.
Product Name : VES001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2023
NMD Pharma Initiates Phase I Safety, Tolerability and Pharmacokinetics Study of NMD1343
Details : NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion channel, and NMD Pharma’s second clinical development candidate
Product Name : NMD1343
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2023
Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial
Details : Data from the trial demonstrated that SAN711 was safe and well tolerated across all dosing cohorts with a favorable absorption and distribution profile. There were no serious adverse events, and all subjects completed the study.
Product Name : SAN711
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2022
Saniona Initiates Positron Emission Tomography (PET) Stage of SAN711 Phase 1 Clinical Trial
Details : SAN711 is an investigational, potential first-in-class positive allosteric modulator of GABA-A α3 receptors, may have the potential to restore spinal inhibitory tone and prevent abnormal pain signaling to the brain.
Product Name : SAN711
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 24, 2022
Details : The termination of the GABAa5 program provides Saniona with rights to a portfolio of more than 800 molecules; the company intends to evaluate their applicability in rare diseases.
Product Name : SAN711
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 11, 2020